Chinese Japanese Germany

Strontium ranelate

Drug for the treatment of osteoporosis Uses
Strontium ranelate
Strontium ranelate
Chemical Name:
Strontium ranelate
Protos;S 12911;Protelos;S 12911-2;TrontiuMranelate;Srtontiumranelate;StrontiuM Ranelic;STRONTIUM RANELATE;Ranelate StrontiuM;StronitiuM ranelate
Molecular Formula:
Formula Weight:
MOL File:

Strontium ranelate Properties

Melting point:
>310°C (dec.)
storage temp. 
-20°C Freezer
H2O: soluble1mg/mL, clear (warmed)
white to beige
CAS DataBase Reference


Hazard Codes  Xn
Risk Statements  20/21/22
Safety Statements  36/37
RIDADR  3077
WGK Germany  3
RTECS  XM7581000
HS Code  29349990

Strontium ranelate price More Price(2)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich SML0596 Strontium ranelate ≥98% (HPLC) 135459-87-9 10mg $49.4 2018-11-20 Buy
Sigma-Aldrich SML0596 Strontium ranelate ≥98% (HPLC) 135459-87-9 50mg $193 2018-11-20 Buy

Strontium ranelate Chemical Properties,Uses,Production

Drug for the treatment of osteoporosis

Strontium ranelate is a drug for the treatment of osteoporosis with its appearance being white to light yellow powder or crystalline powder. It is odorless and slightly soluble in water but almost insoluble in ethanol and easily soluble in dilute hydrochloric acid. It was first studied and developed by the French Servier Company and had first entered into market in November 2004 in Ireland and entered into market in UK in December of same year. Japan's Fujisawa Pharmaceutical Company has owned the authorization of development, production and marketing right of this product in Japan. It is clinically mainly used for the treatment and prevention of osteoporosis in postmenopausal women with significantly reducing the risk of occurrence of vertebral fractures and hip fractures.
Strontium ranelate has dual pharmacological inhibitory effects of both inhibiting bone absorption and promoting bone formation. On the one hand, in the osteoblast-enriched cells, it can increase the synthesis of collagen and non-collagen proteins and promote the osteoblast-mediated bone formation mediated by osteoblasts through enhancing the proliferation of pre-osteoblast. On the other hand, through decreasing the osteoclast differentiation and reabsorbing activity and further reduction of bone absorption, it achieves the rebalance of bone turnover, further boosting the bone formation.
Strontium ranelate mainly exerts its pharmacological effects through its strontium atoms. Strontium is an alkaline earth metal element which is cognate with calcium and located under the calcium in the element periodic table. Its absorption, distribution, excretion is similar with calcium. After oral administration of 2g, the absolute bioavailability of strontium is 27%. Large doses of strontium cause abnormalities of bone mineral metabolism with low doses of strontium being able to the enhance the pre-osteoblast replication, increasing the number of osteoblasts to stimulate bone formation while reducing the activity of osteoclasts, reducing osteoclast quantity as well as reducing the rate of bone absorption. The results are consistent with the results found in animal and human in vivo studies.
s (OP) is a progressive skeletal disease, characterized by reduced bone mineral density (BMD) and degenerative changes in bone tissue microstructure. It is exhibited as bone fragility and fracture-prone with the latter most commonly happening in the spine, hip and wrist. For women, when after surgical removal of the ovaries or menopause, the body stops producing bone to maintain strong estrogen, thus, primary OP is particularly common in post-menopausal or menopausal women.
There are currently two major kinds of drugs used in the treatment of osteoporosis: one kind includes those drugs that inhibits osteoclast activity and therefore inhibiting bone absorption such as bisphosphonates, estrogen and calcitonin; the second category includes those drugs which promote the osteoblast activity, and thereby stimulating bone formation and there are currently only a product, human recombinant parathyroid hormone 1-34, that has entered into market. It however requires injection with high drug prices.
The above information is edited by the chemicalbook of Dai Xiongfeng.


It is mainly used for the treatment and prevention of osteoporosis in postmenopausal women and significantly reduces the risk of occurrence of vertebral fractures and hip fractures.

Chemical Properties

Crystalline Solid


Bone metabolism modulator; inhibits bone resorption while maintaining bone formation. Antiosteoporotic


Strontium ranelate (Protelos) is a strontium(II) salt of ranelic acid for (-)-desmethoxyverapamil binding to calcium channel with IC50 of 0.5 mM.

Strontium ranelate Preparation Products And Raw materials

Raw materials

Preparation Products

Strontium ranelate Suppliers

Global( 202)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 CHINA 3217 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 22049 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20786 55
Nanjing Finetech Chemical Co., Ltd.
025-85710122 17714198479
025-85710122 CHINA 894 55
Hubei Jusheng Technology Co.,Ltd.
86-155-27864001 CHINA 18004 58
Jinan Jianfeng Chemical Co., Ltd
15562555968 CHINA 617 58
0086-13720134139 CHINA 955 58
Jinan Tenglong Chemical Co.,Ltd
Whatsapp:+8615563263311 Skype:live:smions7080 CHINA 778 58
career henan chemical co
+86-371-86658258 CHINA 19990 58
J & K SCIENTIFIC LTD. 400-666-7788 +86-10-82848833
+86-10-82849933; China 96815 76

View Lastest Price from Strontium ranelate manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-08-20 Strontium ranelate
US $1.00 / KG 1G 98% 100KG career henan chemical co
2018-07-26 Strontium ranelate
US $100.00 / KG 1KG 98% 100KG career henan chemical co

135459-87-9(Strontium ranelate)Related Search:

  • 2,2'-((5-Carboxy-4-(carboxymethyl)-3-cyanothiophen-2-yl)azanediyl)diacetic acid, distrontium s
  • distrontium renelate
  • 5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-3-thiopheneacetic acid strontium salt (1:2)
  • 5-[Bis(carboxymethyl)amino]-2-carboxy-4-cyano-3-thiopheneacetic Acid Strontium Salt
  • Protelos
  • Protos
  • S 12911
  • S 12911-2
  • Ranelate StrontiuM
  • StrontiuM ranelate (Protelos)
  • 2,2'-((5-Carboxy-4-(carboxyMethyl)-3-cyanothiophen-2-yl)azanediyl)diacetic acid, distrontiuM salt
  • Strontium Ranelate.H2O
  • 3-(3-Cyano-4-carboxymethyl-5-carboxy-2-thienyl)-3-azapentanedioic distrontium salt
  • 3-Thiopheneacetic acid, 5-(bis(carboxymethyl)amino)-2-carboxy-4-cyano-, strontium salt (1:2)
  • Ranelic acid distrontium salt
  • Srtontiumranelate
  • Strontium ranelate heptahydrate
  • TrontiuMranelate
  • StronitiuM ranelate
  • Strontium ranelate, 98%, an antiosteoporotic agent
  • StrontiuM 2,2'-((5-carboxylato-4-(carboxylatoMethyl)-3-cyanothiophen-2-yl)azanediyl)diacetate
  • StrontiuM Ranelic
  • StrontiuM ranelate SynonyMs DistrontiuM renelate
  • 2-[N,N-Di(carboxymethyl)amino]-3-cyano-4-carboxymethylthiophene-5-carboxylic acid strontium salt
  • Ranelic acid strontium salt
  • C12H10N2O8SSr2
  • C12H6N2O8S2Sr
  • Pharmaceutical intermdiate
  • API
  • Other APIs
  • All Inhibitors
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • 135459-87-9
  • 135459-87-1
  • C12H6N2O8SSr2
  • C12H6N2O8SSr27H2O
  • C12H6N2O8SSr88H2O
Copyright 2017 © ChemicalBook. All rights reserved